Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2018-09-13 |
Oxford Biomedica (UK) |
|
|
construction of new premises |
|
Construction of new premises |
2018-09-12 |
Imcheck Therapeutics (France) |
chief scientific officer (CSO) |
|
nomination |
Cancer - Oncology - Autoimmune diseases |
Nomination |
2018-09-11 |
Optibrium (UK) Intellegens (UK) |
predictive modelling platform for drug discovery |
|
development |
Technology - Services |
Development agreement |
2018-09-11 |
Akero Therapeutics (USA - CA) |
president and chief executive officer |
|
nomination |
Liver diseases - Hepatic diseases |
Nomination |
2018-09-11 |
SGS (Switzerland) |
new testing capabilities at Lincolnshire facility |
|
construction of new premises |
Technology - Services |
Construction of new premises |
2018-09-11 |
Amicus Therapeutics (USA - NJ) |
member of the board of directors |
|
nomination |
Rare diseases - Genetic diseases - Metabolic diseases |
Nomination |
2018-09-10 |
Affilofic (France) Samabriva (France) |
Nanofitin®-conjugated biotherapeutics |
lysosomal storage disorders |
licensing |
Rare diseases - Genetic diseases - Metabolic diseases |
Licensing agreement |
2018-09-10 |
Five Prime Therapeutics (USA - CA) SOLTI (Spain) |
Reolysin® (pelareorep - human reovirus type 3 Dearing strain) |
breast cancer |
clinical research |
Cancer - Oncology |
Clinical research agreement |
2018-09-10 |
Pieris Pharmaceuticals (USA - MA) |
member of the board of directors |
|
nomination |
Cancer - Oncology |
Nomination |
2018-09-10 |
Halozyme Therapeutics (USA - CA) |
member of the board of directors |
|
nomination |
Cancer - Oncology |
Nomination |
2018-09-10 |
Glythera, now Iksuda Therapeutics (UK) |
|
|
restructuring - corporate name change |
Cancer - Oncology |
Restructuring |
2018-09-10 |
Thrombogenics (Belgium) now Oxurion (Belgium) |
|
|
|
Ophtalmological diseases |
Restructuring |
2018-09-10 |
Medivir (Sweden) |
chief medical officer |
|
nomination |
|
Nomination |
2018-09-06 |
Leukocare (Germany) Xellia Pharmaceuticals (Denmark) |
new formulations for anti-infective products |
|
research - development - R&D |
Infectious diseases |
Research agreement |
2018-09-06 |
Eli Lilly (USA - IN) Imperial College London (UK) UCL (UK) |
Process Systems Engineering (PSE) methods |
|
collaboration - research |
Technology - Services |
Research agreement |
2018-09-06 |
Oncolytics Biotech (Canada) Roche (Switzerland) |
atezolizumab (Tecentriq®) |
|
collaboration - supply agreement |
|
Collaboration agreement |
2018-09-04 |
Radius Health (USA - MA) |
chief medical officer |
|
nomination |
Bone diseases - Cancer - Oncology |
Nomination |
2018-09-04 |
Ziopharm Oncology (USA - MA) |
member of the board of directors |
|
nomination |
Cancer - Oncology |
Nomination |
2018-09-04 |
Tmunity Therapeutics, (USA - PA) |
executive vice-president |
|
nomination |
Cancer - Oncology |
Nomination |
2018-08-30 |
Eli Lilly (USA - IN) |
senior vice president |
|
nomination |
|
Nomination |